Gastroparesis Clinical Trial
Official title:
Body Surface Gastric Mapping to Evaluate Patients With Upper Gastrointestinal Symptoms and Controls
Verified date | February 2023 |
Source | University of Calgary |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This is an analytical validation observational cohort study is designed to provide evidence of: safety and reliability of Body Surface Gastric Mapping using the Gastric Alimetry System (GAS), normal reference values, and correlation of metrics with patient symptoms among healthy adults and patients diagnosed with upper abdominal motility disorders. GAS is intended to record, store, view and process gastric myoelectrical activity. This is a proprietary system consisting of multiple electrodes arranged on an array that is placed precisely over the stomach, a reader to collect the electrode measurements and a smart tablet application to track patient reported symptoms. Participants meeting inclusion and exclusion criteria will continue fasting for 30 minutes after the Gastric Alimetry System has been applied and begun measuring, eat a standard study meal within 10 minutes and remain quietly seated, reclining, for 4 hours as the GAS continues to collect data. The array is removed and the abdomen is examined for evidence of skin effects.
Status | Enrolling by invitation |
Enrollment | 200 |
Est. completion date | December 31, 2024 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: Healthy Population: - Adults aged 18 years and over - Able to understand the risks/benefits of the study - Able to give written informed consent - No active gastrointestinal symptoms or pathology - Resides in the Calgary, Alberta area Patient Population: - Adults aged 18 years and over - BMI > 35 - Able to understand the risks/benefits of the study - Able to give written informed consent - Patients meeting Rome IV Criteria for functional dyspepsia, or a nausea and vomiting disorder - Patients with gastroparesis defined on a standardized gastric scintigraphy study - Resides in the Calgary, Alberta area Exclusion Criteria: Healthy Population: - Under 18 years of age - BMI > 35 - Taking medications known to affect GI motility or the mid-gut axis (eg antidepressants, anti-anxiety medication, prokinetics, opiates) - Metabolic, neurogenic, or endocrine disorders known to cause gastrointestinal dysmotility (eg. Multiple Sclerosis, Parkinson's disease, hypothyroidism) - Known current GI infection (includes H. pylori when being actively treated) - Known current inflammatory bowel disease - Known current GI malignancy - Known GI functional or motility disorders - Previous gastroduodenal surgery - GI functional or motility disorders - Pregnant women - Open abdominal wounds or abdominal skin not intact (eg rash, abrasions, weeping tissue) - Fragile skin evidence by high susceptibility to skin tears or skin that bruises and breaks easily - Allergy to adhesives - History of allergy or intolerance to ingredients in the meal (nutrient drink, Ensure or similar and Clif bar or similar) - No vulnerable groups such as; prisoners, individuals with known cognitive impairment, or institutionalised individuals be involved - Regular cannabis use - Diagnosed with, or suspected to have life-threatening conditions that could result in immediate danger Patient Population: - Under 18 years of age - BMI > 35 - Metabolic, neurogenic, or endocrine disorders known to cause gastrointestinal dysmotility (eg. Multiple Sclerosis, Parkinson's disease, hypothyroidism) - Known current GI infection (includes H. pylori when being actively treated) - Known current inflammatory bowel disease - Known current GI malignancy - Previous gastroduodenal surgery - Open abdominal wounds or abdominal skin not intact (eg rash, abrasions, weeping tissue) - Fragile skin evidence by high susceptibility to skin tears or skin that bruises and breaks easily - Allergy to adhesives - Pregnant women - History of allergy or intolerance to ingredients in the meal (nutrient drink, Ensure or similar and Clif bar or similar) - No vulnerable groups such as; prisoners, individuals with known cognitive impairment, or institutionalised individuals be involved - Regular cannabis use except in the case of CHS - Diagnosed with, or suspected to have life-threatening conditions that could result in immediate danger - Inability to remain in a relaxed reclined position for the test duration |
Country | Name | City | State |
---|---|---|---|
Canada | University of Calgary | Calgary | Alberta |
Lead Sponsor | Collaborator |
---|---|
University of Calgary |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Gastric electrical signal frequency | Successful detection of gastric electrical signal in the 2-5 cycle-per-minute (cpm) spectrum as defined by reference ranges at Reliability of 90% and Confidence Interval (CI) of 95% | Pre-meal | |
Primary | Gastric electrical signal frequency | Successful detection of gastric electrical signal in the 2-5 cycle-per-minute (cpm) spectrum as defined by reference ranges at Reliability of 90% and Confidence Interval (CI) of 95% | Post meal at 1 hour | |
Primary | Gastric electrical signal frequency | Successful detection of gastric electrical signal in the 2-5 cycle-per-minute (cpm) spectrum as defined by reference ranges at Reliability of 90% and Confidence Interval (CI) of 95% | Post meal at 2 hours | |
Primary | Gastric electrical signal frequency | Successful detection of gastric electrical signal in the 2-5 cycle-per-minute (cpm) spectrum as defined by reference ranges at Reliability of 90% and Confidence Interval (CI) of 95% | Post meal at 3 hours | |
Primary | Gastric electrical signal frequency | Successful detection of gastric electrical signal in the 2-5 cycle-per-minute (cpm) spectrum as defined by reference ranges at Reliability of 90% and Confidence Interval (CI) of 95% | Post meal at 4 hours | |
Primary | Gastric electrical signal amplitude | Estimation of the power of the gastric electrical signal in the above frequency spectrum (µV) at a Reliability of 90% and Confidence Interval (CI) of 95% | Pre-meal | |
Primary | Gastric electrical signal amplitude | Estimation of the power of the gastric electrical signal in the above frequency spectrum (µV) at a Reliability of 90% and Confidence Interval (CI) of 95% | Post meal at 1 hour | |
Primary | Gastric electrical signal amplitude | Estimation of the power of the gastric electrical signal in the above frequency spectrum (µV) at a Reliability of 90% and Confidence Interval (CI) of 95% | Post meal at 2 hours | |
Primary | Gastric electrical signal amplitude | Estimation of the power of the gastric electrical signal in the above frequency spectrum (µV) at a Reliability of 90% and Confidence Interval (CI) of 95% | Post meal at 3 hours | |
Primary | Gastric electrical signal amplitude | Estimation of the power of the gastric electrical signal in the above frequency spectrum (µV) at a Reliability of 90% and Confidence Interval (CI) of 95% | Post meal at 4 hours | |
Primary | Safety - abdominal skin effects | Incidence of skin irritation from the electrodes / adhesive, discomfort associated with device wear or removal | After removal of Gastric Alimetry array at approximately 4.2 hours post meal | |
Primary | Safety - abdominal skin effects | Incidence of skin irritation from the electrodes / adhesive, discomfort associated with device wear or removal | 24 hours post study visit | |
Primary | Safety - abdominal skin effects | Incidence of skin irritation from the electrodes / adhesive, discomfort associated with device wear or removal | 7 days post study visit | |
Primary | Upper Gastric Symptoms - nausea, bloating, upper gut pain, heartburn, stomach burn, excessively full | Self reported assessment of symptoms on a scale of 0-10 with 10 being most severe imaginable | Pre-meal | |
Primary | Upper Gastric Symptoms - nausea, bloating, upper gut pain, heartburn, stomach burn, excessively full | Self reported assessment of symptoms on a scale of 0-10 with 10 being most severe imaginable | Post meal at 1 hour | |
Primary | Upper Gastric Symptoms - nausea, bloating, upper gut pain, heartburn, stomach burn, excessively full | Self reported assessment of symptoms on a scale of 0-10 with 10 being most severe imaginable | Post meal at 2 hours | |
Primary | Upper Gastric Symptoms - nausea, bloating, upper gut pain, heartburn, stomach burn, excessively full | Self reported assessment of symptoms on a scale of 0-10 with 10 being most severe imaginable | Post meal at 3 hours | |
Primary | Upper Gastric Symptoms - nausea, bloating, upper gut pain, heartburn, stomach burn, excessively full | Self reported assessment of symptoms on a scale of 0-10 with 10 being most severe imaginable | Post meal at 4 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03941288 -
Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia
|
Phase 2 | |
Terminated |
NCT03285308 -
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01
|
Phase 3 | |
Completed |
NCT00733551 -
Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Doses of GSK962040 Administered to Healthy Adult Subjects.
|
Phase 1 | |
Completed |
NCT01650714 -
Endoscopic Full Thickness Biopsy, Gastric Wall.
|
N/A | |
Completed |
NCT01452815 -
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
|
Phase 2 | |
Completed |
NCT01039974 -
GSK962040 Drug-drug Interaction Study With Ketoconazole
|
Phase 1 | |
Terminated |
NCT04844190 -
Use of EndoFLIP and Manometry Prior to G-POEM
|
N/A | |
Enrolling by invitation |
NCT06215547 -
Medtronic Enterra II Neurostimulator
|
N/A | |
Completed |
NCT04026997 -
A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis
|
Phase 2 | |
Completed |
NCT00562848 -
A Study to Evaluate Safety, Side Effects, Muscle Activity and Speed of Gastric Emptying of GSK962040
|
Phase 1 | |
Enrolling by invitation |
NCT04207996 -
Vagus Nerve Response in Gastroparesis Patients
|
||
Completed |
NCT04607304 -
ABCA2 GIRMS Analytical Validation Clinical Performance Study
|
N/A | |
Recruiting |
NCT06068114 -
Gastric Pathophysiology in Diabetes
|
||
Completed |
NCT03259841 -
Ultrasound Assessment of Gastric Contents in Fasted Patient Undergoing Cholecystectomy
|
||
Active, not recruiting |
NCT04300127 -
Pioglitazone for Idiopathic Gastroparesis
|
Early Phase 1 | |
Recruiting |
NCT01696734 -
Domperidone in Treating Patients With Gastrointestinal Disorders
|
Phase 3 | |
Terminated |
NCT04635306 -
13C-Spirulina Nitrogen Content GEBT Study
|
N/A | |
Withdrawn |
NCT02420925 -
Effect of Celiac Plexus Block on Gastric Emptying and Symptoms Caused by Gastroparesis
|
N/A | |
Recruiting |
NCT00777439 -
Domperidone for Refractory Gastrointestinal Disorders
|
N/A | |
Terminated |
NCT00760461 -
Domperidone in Refractory Gastroparesis
|
Phase 2 |